Among them, GCKR has not been reported as a prognostic biomarker so far; only two studies have reported that gastric and colorectal cancer patients with GCKR variates harbored a better prognosis than those of wildtype [42, 43], and our study revealed its prognostic value in gliomas for the first time. This evidence concerns the gene GCKR and glioma.